Medtronic PLC (MDT)

Nov 13, 2026

This article identifies four healthcare dividend stocks—Bristol-Myers Squibb, Medtronic, AbbVie, and Johnson & Johnson—suitable for retirees due to their rising dividends, stability, and ability to withstand recessions. It details each company's yield, dividend safety, bull case, and risks, highlighting Bristol-Myers Squibb's leading yield of 4.03% and Johnson & Johnson's 64-year dividend raise streak. The piece emphasizes the balance between high current yield and consistent dividend growth for income investors.

Nov 13, 2026

Medtronic PLC (MDT) stock increased by 1.85% to $102.86 on a mixed trading day where the Dow Jones Industrial Average rose and the S&P 500 Index fell. The company's shares closed 3.26% below its 52-week high.

Nov 13, 2026

Barclays has lowered its price target for MiniMed Group (NASDAQ:MMED) from $22.00 to $20.00, while maintaining an "equal weight" rating, suggesting an 11.54% upside. Despite this, the consensus among 19 analysts remains a "Moderate Buy" with an average target of $24.12, and the stock traded up 0.3% to $17.93 on Friday. Several institutional investors also increased their holdings in MiniMed Group during the third quarter.

Nov 12, 2026

MacroGenics (MGNX) reported a Q3 loss of $0.34 per share, significantly missing the Zacks Consensus Estimate of a $0.1 loss, and also failed to meet revenue expectations with $18.67 million against an estimated $61.99 million. Despite outperforming the S&P 500 year-to-date, the biopharmaceutical company holds a Zacks Rank #3 (Hold) due to mixed estimate revisions, suggesting it will perform in line with the market. Investors await management's commentary on the earnings call for insights into future stock movement.

Nov 12, 2026

This article compares Abbott Laboratories (ABT) and Medtronic (MDT) as dividend stocks, analyzing their current yields, dividend growth rates, and financial health. While Medtronic currently has a higher yield, Abbott's faster dividend growth is projected to result in higher total payouts over a 10-year period. The analysis considers upcoming business spin-offs for both companies and their respective free cash flow trends.

Nov 11, 2026

Stereotaxis reported a 20% year-over-year revenue increase to $8.9 million for Q3 2026, driven by new system installations and increased catheter sales. The company is undergoing two major transformations: shifting to easily installed systems like Genesis X and developing disposable interventional catheters for recurring revenue. Despite supply constraints for Magic catheters, Stereotaxis is pursuing alternative options and secured a convertible note financing of up to $24 million to support operations until anticipated profitability within the next year.

Nov 11, 2026

Abbott's UltiSynq defibrillation lead has received simultaneous market approvals in the US and Europe, offering a new option for patients needing both conduction system pacing and defibrillation protection. The approvals were supported by the ASCEND CSP trial, which demonstrated a 97.5% major complication-free rate and high implantation success for the device, designed to treat irregular heart rhythms by directly targeting the heart's natural electrical pathways. This product expands Abbott’s cardiac rhythm management portfolio, providing a solution for patients indicated for implantable cardioverter defibrillator (ICD) or cardiac resynchronisation therapy defibrillator (CRT-D) therapy.

Nov 10, 2026

Medtronic PLC (MDT) shares fell by 1.17% on Tuesday, closing at $101.59, as the broader stock market also experienced a downturn. The company's stock underperformed both the S&P 500 and the Dow Jones Industrial Average, which also saw declines. Medtronic PLC finished the trading session 4.46% below its 52-week high.

Nov 10, 2026

M&G PLC reduced its stake in Medtronic PLC by 4.8% during the third quarter, selling 185,546 shares and now owning 3,716,148 shares valued at $319.59 million. Other institutional investors also adjusted their positions, while Medtronic reported strong earnings, beating analyst estimates with $1.45 EPS and $9.76 billion in revenue. The company also announced a quarterly dividend of $0.72 per share.

Nov 10, 2026

Alps Advisors Inc. increased its stake in Medtronic PLC by 39.8% in the third quarter, purchasing an additional 12,505 shares and bringing its total holdings to 43,963 shares valued at approximately $3.8 million. Medtronic currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $102.88, and recently reported strong quarterly earnings and a dividend of $0.72 per share. Insider selling also occurred, with CEO Geoffrey Martha and EVP Harry Kiil reducing their positions in the company.

Nov 9, 2026

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced the full commercial launch of its VerteGlide® Spinal Growth Guidance System, an innovative solution for Early Onset Scoliosis (EOS). This system aims to correct spinal deformities while preserving the potential for continued spinal growth in children. The successful limited launch highlighted strong demand and adoption, further solidifying OrthoPediatrics' commitment to pediatric-specific orthopedic solutions.

Nov 7, 2026

DexCom (DXCM) stock fell 6.0% on Friday, November 6, 2026, without company-specific news, echoing similar declines in peers Insulet and Tandem Diabetes Care. Tandem's earnings call revealed slower-than-expected pharmacy distribution which could impact 2027 revenue growth, potentially affecting DexCom due to its presence in the same diabetes market. Despite this recent fall, DexCom's shares have returned 34.0% over the past year, significantly outperforming the S&P 500.

Nov 7, 2026

Jake Leach, CEO of Dexcom, rose from a $10-an-hour lab dishwasher to leading a $30 billion healthcare company without ever asking for a promotion. His career path was shaped by hard work, a childhood fascination with engineering, and a personal connection to diabetes through his grandfather. Leach advises young professionals to take initiative, solve big problems, and volunteer for tasks outside their immediate responsibilities to become more valuable leaders.

Nov 6, 2026

S&P Global Ratings has revised Boston Scientific Corp.'s outlook from stable to negative, citing deepening commercial headwinds in its core product franchises and the financial burden of its pending $14.5 billion acquisition of Penumbra Inc. The rating agency expects revenue growth to decelerate sharply through 2028, driven by setbacks in the WATCHMAN and electrophysiology franchises. S&P projects adjusted leverage to exceed its 2.5x downside trigger upon the Penumbra acquisition's close and remain elevated for at least two years, requiring careful management of reinvestment and capital allocation to stabilize credit metrics.

Nov 6, 2026

Brady Family Wealth LLC significantly reduced its stake in Medtronic PLC by 89.8% in the third quarter of 2026, selling 22,025 shares and retaining 2,492 shares valued at $215,000. Despite this, institutional ownership remains high at 82.06%, and Medtronic exceeded analyst expectations for earnings and revenue, with revenue up 13.7% year-over-year. Analysts currently hold a "Moderate Buy" consensus for MDT, with an average price target below its recent trading price, while company executives have also reported share sales.

Nov 5, 2026

Abbott Laboratories (ABT) stock is priced at 42.6 times earnings, higher than five of its peers, despite having a lower operating profit margin at 13.8%. While Abbott's sales growth is strong at 10.0%, comparable to Medtronic's 9.8%, Medtronic trades at a much lower P/E of 25.7 due to its higher operating margin. The article suggests that Abbott's current stock price assumes continued growth and an improvement in its reported operating margin, which has recently declined.

Nov 4, 2026

Smart Sand (SND) is scheduled to release its Q3 2026 earnings after the market closes on Wednesday, November 11th, with analysts anticipating a loss of $0.14 per share on revenues of $29.57 million. The company previously reported an EPS of $0.25 and revenues of $115.05 million. Shares recently opened at $4.68, and insider transactions over the last 90 days indicate sales totaling approximately $446,500.

Nov 3, 2026

Medtronic announced positive primary endpoint results from its SPYRAL AFFIRM post-approval study, demonstrating significant and clinically meaningful blood pressure reductions at six months using the Symplicity Spyral™ renal denervation (RDN) system. Nearly nine out of 10 patients experienced clinical benefits without an increase in antihypertensive medications. Additionally, the U.S. FDA approved an update to the Symplicity Spyral RDN system's labeling, incorporating data for patients with isolated systolic hypertension, chronic kidney disease up to stage 3b, and type 2 diabetes.

Nov 3, 2026

Rockwell Medical has agreed to acquire the majority of Vantive's hemodialysis business for $125 million in base consideration, with an additional $45 million in contingent payments. The deal includes hemodialysis concentrates, machines, water treatment systems, and Vantive's Medolla, Italy manufacturing facility, with the combined entity projected to generate $400-450 million annually. Vantive will retain its dialyzer portfolio and focus on home dialysis and critical care post-divestiture, while Rockwell aims to accelerate its growth in hemodialysis.

Nov 3, 2026

Boston Scientific Corp. (BSX) is trading at a significant discount compared to its historical valuation, driven by weakening earnings expectations and loss of momentum in several key product areas. While the low price-to-earnings ratio might appear attractive, management anticipates performance improvement only by 2028, with 2027 being the trough of the current cycle. The company faces execution risks and intensifying competition, leading to a "Strong Sell" Zacks Rank despite some valuable growth assets and a promising pipeline that is back-end loaded.

Nov 3, 2026

Intuitive Surgical (ISRG) stock trades at a high P/E multiple of 51.6 times earnings, the highest among its healthcare peers, largely due to its superior operating margin and revenue growth. While the company's recurring revenue model and procedure growth support its premium valuation, potential instrument price cuts and a recent litigation settlement impacting net income pose risks. Investors should monitor da Vinci procedure growth when the company reports in January 2027, as a slip in growth could make the stock appear overvalued without its competitive edge.

Nov 3, 2026

Mirae Asset Global Investments Co. Ltd. recently acquired a new position in Medtronic PLC (NYSE:MDT) during the third quarter, purchasing 366,492 shares valued at approximately $31.625 million. Other institutional investors also adjusted their holdings, with a significant 82.06% of the stock now owned by hedge funds and institutional investors. Analysts generally rate Medtronic as a "Moderate Buy" with a consensus price target of $102.88, despite some recent insider selling by executives.

Nov 3, 2026

Hennessy Advisors Inc. significantly reduced its stake in Medtronic PLC by 34.8% in the third quarter, selling 31,426 shares and retaining 58,900 shares valued at approximately $5.08 million. Medtronic exceeded analyst expectations with quarterly adjusted earnings of $1.45 per share and revenue of $9.76 billion, a 13.7% increase year over year. The company's shares were up 2.9% at $99.34, and it maintains a quarterly dividend of $0.72 per share, yielding 2.9% annually, while analysts hold a "Moderate Buy" rating with a consensus price target of $102.88.

Nov 3, 2026

BOCHK Asset Management Ltd has made a new $3.45 million investment in Medtronic PLC, acquiring 40,000 shares of the medical technology company. This comes as Medtronic reported strong quarterly earnings, exceeding analyst estimates, and maintains a quarterly dividend. Analysts hold a "Moderate Buy" rating for the stock, despite recent insider selling activity.

Nov 2, 2026

e.l.f. Beauty (ELF) is set to report its Q3 earnings this Wednesday after market hours. The company exceeded revenue and EPS expectations last quarter, and analysts anticipate a 38.2% year-on-year revenue growth for the upcoming report. Sentiment in the personal care segment has been positive, with e.l.f. Beauty's stock up 6.7% over the last month.

Nov 2, 2026

Medtronic PLC (MDT) shares rose 2.85% to $99.29 on Monday, outperforming a mixed stock market. The Dow Jones Industrial Average gained 0.41%, while the S&P 500 Index fell 0.51%. The company's stock closed 6.62% below its 52-week high.

Nov 2, 2026

A Texas man has filed a product liability lawsuit against Abbott Laboratories, alleging that their sales representatives prevented him from receiving proper medical treatment after his Proclaim Spinal Cord Stimulator System failed. The lawsuit claims that unlicensed sales reps repeatedly tried to reprogram the malfunctioning device, despite the plaintiff experiencing ineffective pain relief and painful shocking, ultimately leading to the implant's removal less than a year after implantation. This case joins a multidistrict litigation with other similar lawsuits against Abbott, Boston Scientific, and Nevro, focusing on defective spinal cord stimulators and inadequate warnings.

Nov 2, 2026

Nippon Life Global Investors Americas Inc. reduced its stake in Medtronic PLC by 14.2% in the third quarter, selling 66,910 shares. The firm now holds 404,280 shares of Medtronic, valued at approximately $35.2 million. Medtronic recently reported strong quarterly earnings, beating analyst expectations, and pays a quarterly dividend of $0.72 per share, yielding 3.0%.

Nov 1, 2026

Shares of Intuitive Surgical fell despite a 22% revenue jump, a reaction the article attributes to investors overlooking the company's main revenue driver. The key insight is that while competition in surgical robotics is increasing, Intuitive Surgical's significant installed base of da Vinci systems generates substantial recurring revenue from instruments, accessories, and services, which far outweighs new robot sales. This recurring revenue stream and the growing demand for robotic surgery provide a strong foundation for future growth.

Nov 1, 2026

Shares of Intuitive Surgical fell despite a 22% revenue jump, with investors seemingly concerned about increasing competition from Medtronic and Johnson & Johnson. However, the company's main revenue driver is not the sale of its da Vinci surgical robots, but rather the recurring income from instruments, accessories, and services for its large installed base. The article suggests that this annuity-like cash flow and continued growth in robotic procedures mean ample room for future growth despite new market entrants.

Nov 1, 2026

Shares of Intuitive Surgical (NASDAQ: ISRG) dropped despite a 22% revenue increase after its recent earnings report, leading investors to miss the true driver of the company's revenue. While competition in surgical robotics is increasing, Intuitive Surgical's growth is sustained by its recurring revenue from instruments, accessories, and services, which account for about 75% of its top line, rather than just the sale of new da Vinci systems. The company's large installed base of over 12,000 systems provides a stable "annuity-like cash flow machine" and there's still significant room for market growth.

Nov 1, 2026

Shares of ResMed (RMD) fell 9.1% on October 30, 2026, despite beating analysts' earnings and revenue estimates for its fiscal first-quarter 2027. The decline was attributed to slower revenue growth, which marked the slowest expansion in five quarters, and a broader market selloff in AI shares. Although other peers also declined, ResMed experienced the steepest drop among them and against its own healthcare sector.

Oct 30, 2026

Stryker (SYK) shares plummeted 10% after its Q3 earnings and revenue missed estimates, leading to a significant cut in its 2026 organic sales guidance, though the EPS cut was much smaller due to margin absorption. The company's new CEO inherits a situation where hip and knee market growth has stalled, and sales execution around its Mako robot is identified as a bottleneck. Investors are now looking to the 2027 guidance for clarity on whether this marks a manageable reset or a more persistent issue for the medical device maker.

Oct 30, 2026

Soltis Investment Advisors LLC significantly increased its stake in Medtronic PLC (NYSE:MDT) by 26.5%, purchasing an additional 35,100 shares to bring its total holdings to 167,746 shares valued at approximately $14.5 million. This acquisition highlights institutional confidence, despite recent insider sales totaling nearly $5.9 million. Medtronic reported strong quarterly earnings, exceeding analyst expectations, and offers a 3.0% annual dividend yield.